We are live on ! Find out more
MAP

Madison Avenue Partners Portfolio holdings

AUM $2.3B
1-Year Est. Return 115.82%
This Fund
S&P 500
This Quarter Est. Return
+8.04%
1 Year Est. Return
+115.82%
3 Year Est. Return
+241.12%
5 Year Est. Return
+319.41%
10 Year Est. Return
–
AUM
$620M
AUM Growth
-$88.4M
Cap. Flow
-$116M
Cap. Flow %
-18.79%
Top 10 Hldgs %
92.19%
Holding
24
New
5
Increased
4
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
WLY icon
John Wiley & Sons Class A
WLY
+$46.8M
2
GMED icon
Globus Medical
GMED
+$37.8M
3
NNI icon
Nelnet
NNI
+$25.5M
4
MCHB
Mechanics Bancorp
MCHB
+$12.4M
5
TSVT
2seventy bio
TSVT
+$3.19M

Top Sells

Rank Stock Value
1
SN icon
SharkNinja
SN
+$99.2M
2
IART icon
Integra LifeSciences
IART
+$45.4M
3
GIII icon
G-III Apparel Group
GIII
+$45M
4
VSTS icon
Vestis
VSTS
+$28.5M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$24.5M

Sector Composition

Rank Sector Weight
1 Industrials 26.1%
2 Healthcare 22.4%
3 Consumer Discretionary 18.56%
4 Communication Services 15.58%
5 Energy 7.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHC icon
1
Graham Holdings Company
GHC
$4.97B
$162M 26.1%
210,717
+1,316
+0.6% +$942K
SN icon
2
SharkNinja
SN
$21B
$113M 18.16%
1,807,237
-1,874,677
-51% -$99.2M
TBPH icon
3
Theravance Biopharma
TBPH
$874M
$62.9M 10.15%
7,012,226
– –
WLY icon
4
John Wiley & Sons Class A
WLY
$2.52B
$52.1M 8.41%
+1,366,771
New +$46.8M
HES
5
DELISTED
Hess
HES
$45.8M 7.39%
300,270
– –
STGW icon
6
Stagwell
STGW
$1.84B
$44.5M 7.17%
7,147,662
– –
GMED icon
7
Globus Medical
GMED
$10.4B
$37.7M 6.09%
+703,276
New +$37.8M
NNI icon
8
Nelnet
NNI
$4.79B
$27.5M 4.43%
+290,213
New +$25.5M
MCHB
9
Mechanics Bancorp
MCHB
$3.47B
$13.6M 2.2%
+905,022
New +$12.4M
TSVT
10
DELISTED
2seventy bio
TSVT
$13M 2.1%
2,433,222
+678,434
+39% +$3.19M
OVID icon
11
Ovid Therapeutics
OVID
$435M
$11.1M 1.8%
3,648,509
– –
ONL
12
Orion Office REIT
ONL
$148M
$9.19M 1.48%
2,618,529
-371,036
-12% -$1.66M
FSP
13
Franklin Street Properties
FSP
$44.8M
$7.47M 1.21%
3,291,443
– –
MACK
14
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$5.72M 0.92%
387,221
-165,864
-30% -$2.33M
GOSS icon
15
Gossamer Bio
GOSS
$66.5M
$4.89M 0.79%
4,140,773
-913,699
-18% -$1.01M
CEE
16
Central and Eastern Europe Fund
CEE
$135M
$4.03M 0.65%
422,823
+148,866
+54% +$1.44M
INDV icon
17
Indivior Pharmaceuticals
INDV
$4.79B
$3.49M 0.56%
162,895
+90,640
+125% +$1.7M
ATMU icon
18
Atmus Filtration Technologies
ATMU
$4.37B
$2.47M 0.4%
+76,732
New +$1.84M
GIII icon
19
G-III Apparel Group
GIII
$1.47B
– –
-1,323,110
Closed -$45M
IART icon
20
Integra LifeSciences
IART
$1.54B
– –
-1,042,156
Closed -$45.4M
RNAC icon
21
Cartesian Therapeutics
RNAC
$232M
– –
-19,420
Closed -$402K
VSTS icon
22
Vestis
VSTS
$2.06B
– –
-1,346,980
Closed -$28.5M
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-417,427
Closed -$24.5M
SFE
24
DELISTED
Safeguard Scientifics, Inc.
SFE
– –
-264,049
Closed -$207K

Similar funds

LCM
Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return
LFM
LGT Fund Management Vaduz, Liechtenstein $2.3B AUM 22.66% 1-Year Est. Return
GCP
Greenoaks Capital Partners Orinda, California $2.3B AUM 19.87% 1-Year Est. Return
ST
Smithfield Trust Pittsburgh, Pennsylvania $2.3B AUM 14.87% 1-Year Est. Return
NSAM
North Star Asset Management Neenah, Wisconsin $2.31B AUM 10.09% 1-Year Est. Return
EPM
Elm Partners Management Philadelphia, Pennsylvania $2.31B AUM 16.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ABI
Abrams Bison Investments Bethesda, Maryland $2.31B AUM 40.26% 1-Year Est. Return

Madison Avenue Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Madison Avenue Partners held 24 positions worth $620M, down 12% from $708M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Madison Avenue Partners withdrew a net $116M in Q1 2024, closing 6 positions and reducing 4 holdings. Its most notable exit was Integra LifeSciences, an estimated $45.4M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Madison Avenue Partners opened a new position in John Wiley & Sons Class A worth $52.1M.

  • Madison Avenue Partners's largest Q1 2024 buy was John Wiley & Sons Class A: 1,366,771 shares worth $52.1M.
  • Madison Avenue Partners added most to 2seventy bio in Q1 2024, an estimated $3.19M increase.
  • Madison Avenue Partners's biggest Q1 2024 reduction was SharkNinja, cutting an estimated $99.2M.
  • Madison Avenue Partners fully exited Integra LifeSciences in Q1 2024, selling an estimated $45.4M.
  • Madison Avenue Partners's ten largest holdings make up 92% of its $620M portfolio in Q1 2024.
  • Madison Avenue Partners opened 5 new positions and closed 6 in Q1 2024.
  • Madison Avenue Partners's portfolio value fell 12% quarter-over-quarter to $620M.

Based on Madison Avenue Partners's 13F filing for Q1 2024, filed 15 May 2024.